Endocrine Testing Market - By Test Type (Human Chorionic Gonadotropin (hCG) Hormone Test, Insulin Test), By Technology (Mass Spectroscopy, Immunoassay), By End-use (Hospitals, Clinical Laboratories) & Forecast, 2023 – 2032

Endocrine Testing Market - By Test Type (Human Chorionic Gonadotropin (hCG) Hormone Test, Insulin Test), By Technology (Mass Spectroscopy, Immunoassay), By End-use (Hospitals, Clinical Laboratories) & Forecast, 2023 – 2032

Endocrine Testing Market Size

Endocrine Testing Market size was valued at around USD 2.5 billion in 2022 and is expected to grow at 8.4% CAGR from 2023 to 2032. The market revenue is estimated to reach USD 5.8 billion by 2032.The increasing prevalence of chronic conditions such as diabetes, thyroid, and obesity are projected to accelerate the business growth.
 

According to International Diabetes Federation data, in 2021, around 140.9 million individuals were suffering from diabetes in China. Additionally, factors such as the rising prevalence of endocrine disorders, the growing aging population affected by chronic conditions, and increased awareness regarding disease testing are further set to propel the industry progress. Also, the raising preference for routine health monitoring and technological advancements is proliferating the market expansion.
 

Endocrine testing is a type of medical testing used to evaluate the function of the endocrine system that consists of a group of glands that produce hormones. These hormones are essential for regulating various bodily functions, including growth and development, metabolism, reproduction, and mood. Endocrine testing may involve analysing the levels of hormones or other biomarkers in the blood, urine, or saliva, or it may involve imaging tests such as ultrasounds or CT scans. The results of endocrine testing are used to further diagnose and monitor endocrine disorders such as diabetes, thyroid disorders, and infertility, as well as to guide treatment decisions and monitor the effectiveness of treatment.
 

The development of endocrine testing technologies can be expensive due to the complex nature of the endocrine system and the wide variety of hormones and biomarkers that need to be measured. Additionally, developing accurate and reliable tests can be time-consuming and require extensive research & development. There are also regulatory requirements that need to be met before new endocrine tests can be approved for use in clinical settings. These factors contribute to the high cost of developing endocrine testing technologies.
 

Moreover, the lack of awareness regarding endocrine testing, especially in the developing countries might impede the revenue progression. However, the benefits of accurate endocrine testing for diagnosis and treatment of endocrine disorders, as well as for monitoring overall health and wellness, can be significant, making the investment worthwhile for healthcare providers, researchers, and patients.
 

COVID-19 Impact

The recent outbreak of COVID-19 has negatively impacted the endocrine testing market share. The lucrative demand for COVID-19 testing has substantially impacted other disease testing services. During the initial period, the incidence, as well as the mortality rate of COVID-19, was highest, and people tended to avoid any other treatment or diagnosis procedures at facilities. The risk of infection during endocrine testing at point-of-care facilities has resulted in procedure deferral. The disruption in point-of-care testing services, difficulties in product distribution, and supply chain with movement restrictions across borders has further impacted the revenue of these industry players amidst a pandemic. These developments, majorly defined by the reduced endocrine testing volume negatively hampered the market in 2020.
 

Endocrine Testing Market Trends

The increasing prevalence of chronic conditions such as thyroid, diabetes, obesity, etc. is anticipated to spur the market expansion significantly. As per the United Nations Food and Agriculture Organization (FAO), in 2020, chronic diseases accounted for around 60% of the global 56.5 million reported fatalities and nearly 46% of the world’s disease burden.
 

Additionally, obesity is recognized as one of the risk factors for both the occurrence and evaluation of other co-morbid conditions. Unhealthy body weight coupled with lack of exercise and physical movement in obese people is a cornerstone in growing concerns regarding osteoarthritis. According to the Centers for Disease Control and Prevention (CDC), the U.S. obesity prevalence accounted for 41.9% in 2021. These statistics indicate conducive scenario for the market growth as the incidence & prevalence of these chronic conditions drives the adoption of endocrine testing.
 

Also, the growing prevalence of endocrine conditions are projected to foster the industry expansion. Endocrine and metabolic diseases are among the most common contemporary human afflictions, particularly in the U.S. and other countries with generous nutrition & screening programs for high-risk individuals. According to the National Centers for Biotechnology Information (NCBI) study, in 2022, the prevalence of endocrine disorders in adults in the U.S. is estimated to be around 5%.
 

Endocrine Testing Market Analysis

Based on test type, the endocrine testing market is segmented as human chorionic gonadotropin (hCG) hormone test, luteinizing hormone (LH) test, progesterone test, thyroid stimulating hormone (TSH) test, prolactin test, insulin test, and others. Human chorionic gonadotropin (hCG) hormone test segment is projected to exceed USD 1.6 billion by 2032. This is primarily owing several advantages offered by hCG test. Preference for numerous easy-to-use diagnostic kits and demand for quantitative estimation related to hCG at healthcare facilities. Additionally, the determination of hCG levels to identify the abnormalities during multiple phases of pregnancy coupled with the rising number of fertile female population is also bolstering the business revenue.
 

Based on technology, the endocrine testing market is segmented as mass spectroscopy, immunoassay, chromatography, nucleic acid based, and others. The immunoassay segment is projected to grow at a 7.8% CAGR from 2023-2032. Clinical endocrinology is associated with laboratory medication as the hormone quantification is crucial for diagnosis, therapeutics, and prognosis of endocrine conditions. Novel interferences are emerging in immunoassays with the advancements in therapies.
 

Analytical mechanisms have also been researched to be quicker and effective with advantages of the automation address the demands of an augmented workload and the need for rapid analysis. Also, these advancements have been simultaneously improving and eliminating certain drawbacks associated with the interferences, in the previous systems.
 

Based on end-use, the endocrine testing market is segmented as hospitals, clinical laboratories, diagnostic centers, and others. The clinical laboratories segment was valued at over USD 1.3 billion in 2022. This is owing to the availability of specialized and efficient diagnoses with rising awareness related to endocrine diseases. The expansion of clinical laboratory chains with advancing infrastructure offering a wide spectrum of clinical testing services for several conditions range of diseases is set to proliferate the segment revenue. Additionally, the use of advanced screening mechanisms at clinical laboratories drives patient preference.
 

The U.S. endocrine testing market is anticipated to reach more than USD 2.1 billion by 2032. The increasing prevalence of endocrine disorders such as diabetes, thyroid disorders, and obesity coupled with supportive reimbursing bodies, & availability of multiple diagnostic firms are driving the demand for endocrine testing. Also, the U.S. market is witnessing a shift towards personalized medicine, wherein the patients receive individualized treatment based on their genetic makeup, lifestyle, and other factors.
 

There is also a growing trend towards digitalization in the market, with the availability of online platforms and apps that allow patients to access their test results and communicate with healthcare providers remotely. Moreover, the increased research grants & fundings would prove beneficial for the market demand. For instance, the American Thyroid Association, an association aimed at supporting the research for treatment of thyroid conditions have funded more than USD 2.8 million across 105 grants. Additionally, the presence of major players in the country and novel product offerings further propels the business statistics.
 

Endocrine Testing Market Share

Some of the major players operating in the endocrine testing industry are

• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• bioMérieux SA
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG 
• Abbott Laboratories, Inc.
   

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion.
 

Endocrine Testing Industry News

• In March 2021, Abbott Laboratories launched the Alinity m Diagnostics System that offers automation and advanced technology for immunoassay testing. The system provides high throughput and quick turnaround time for endocrine and other diagnostic testing. This launch helped the company to introduce innovative products, further offering a competitive edge.
   
• In February 2021, Siemens Healthineers introduced the Atellica Solution for Endocrinology, which is a comprehensive, fully automated immunoassay system for endocrine testing. The system enables accurate and reliable results for a wide range of hormones and markers. This product launch helped the company to strengthen its product portfolio across the market.
   

Endocrine testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Test Type, 2018 - 2032 (USD Million & Units)

• Human Chorionic Gonadotropin (hCG) Hormone Test
• Luteinizing Hormone (LH) Test
• Progesterone Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Insulin Test
• Others

By Technology, 2018 - 2032 (USD Million)

• Mass Spectroscopy
• Immunoassay
• Chromatography
• Nucleic Acid Based
• Others

By End-use, 2018 - 2032 (USD Million)

• Hospitals
• Clinical Laboratories
• Diagnostic Centers
• Others  

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey